CO6910163A2 - Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de proteína convertasa subtilisina kexina-9 (pcsk9) - Google Patents

Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de proteína convertasa subtilisina kexina-9 (pcsk9)

Info

Publication number
CO6910163A2
CO6910163A2 CO14054971A CO14054971A CO6910163A2 CO 6910163 A2 CO6910163 A2 CO 6910163A2 CO 14054971 A CO14054971 A CO 14054971A CO 14054971 A CO14054971 A CO 14054971A CO 6910163 A2 CO6910163 A2 CO 6910163A2
Authority
CO
Colombia
Prior art keywords
pcsk9
administering
inhibitor
methods
convertase subtilisin
Prior art date
Application number
CO14054971A
Other languages
English (en)
Inventor
Gary Swergold
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6910163(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO6910163A2 publication Critical patent/CO6910163A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO14054971A 2011-09-16 2014-03-14 Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de proteína convertasa subtilisina kexina-9 (pcsk9) CO6910163A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535392P 2011-09-16 2011-09-16
US201161559162P 2011-11-14 2011-11-14
US201261641321P 2012-05-02 2012-05-02

Publications (1)

Publication Number Publication Date
CO6910163A2 true CO6910163A2 (es) 2014-03-31

Family

ID=46881178

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14054971A CO6910163A2 (es) 2011-09-16 2014-03-14 Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de proteína convertasa subtilisina kexina-9 (pcsk9)

Country Status (21)

Country Link
US (2) US10076571B2 (es)
EP (3) EP2756004B1 (es)
JP (2) JP6158813B2 (es)
KR (1) KR101964031B1 (es)
CN (2) CN103930444B (es)
AR (1) AR087881A1 (es)
AU (1) AU2012308797B2 (es)
BR (1) BR112014005522A2 (es)
CA (1) CA2848201C (es)
CL (1) CL2014000605A1 (es)
CO (1) CO6910163A2 (es)
EA (1) EA028278B1 (es)
ES (2) ES2773111T3 (es)
IL (1) IL231011B (es)
MA (1) MA35430B1 (es)
MX (1) MX363642B (es)
MY (1) MY170089A (es)
SG (1) SG2014010524A (es)
TW (1) TWI601740B (es)
WO (1) WO2013039969A1 (es)
ZA (1) ZA201401114B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
CA2825838C (en) 2011-01-28 2020-10-27 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
PL3055333T4 (pl) * 2013-10-11 2020-07-27 Sanofi Biotechnology Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
JP6720079B2 (ja) * 2013-12-17 2020-07-08 カイマブ・リミテッド 対象とするヒト標的に特異的に結合するリガンド
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
CN106029096A (zh) * 2014-02-14 2016-10-12 瑞泽恩制药公司 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6741590B2 (ja) 2014-04-25 2020-08-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア コレステロールレベルを低下させるためのｌｄｌｒ変異体および組成物中でのそれらの使用
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3169353B1 (en) * 2014-07-16 2019-12-18 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
CA2955304C (en) * 2014-07-16 2023-12-12 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
CA2978204A1 (en) * 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
MA43570A (fr) 2015-12-11 2018-11-14 Univ Pennsylvania Thérapie génique pour traiter l'hypercholestérolémie familiale
MX2018007925A (es) 2015-12-31 2018-08-29 Jiangsu Hengrui Medicine Co Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
JP7103748B2 (ja) * 2016-10-05 2022-07-20 サッポロビール株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2018220212A1 (en) 2017-02-20 2019-08-08 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
WO2018189705A1 (en) 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
TW201945401A (zh) * 2018-03-06 2019-12-01 法商賽諾菲生物技術公司 降低心血管風險的方法
CA3105071A1 (en) * 2018-07-02 2020-01-09 Abcentra, Llc Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
EP0797999A3 (en) 1996-03-26 2002-09-25 Eli Lilly And Company Formulations of obesity protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2484399A (en) 1998-01-30 1999-08-16 Scios Inc. Controlled release delivery of peptide or protein
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
EP1257572A2 (en) 2000-02-07 2002-11-20 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
DE602004028115D1 (de) 2003-05-02 2010-08-26 Univ College Cork Nat Univ Ie Lichtemittierende mesastrukturen mit hohem höhe-zu-breite-verhältnis und quasi-parabolischen seitenwänden und ihre herstellung
JP4931597B2 (ja) 2003-11-07 2012-05-16 イミュネックス・コーポレーション インターロイキン−４受容体を結合する抗体
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
CN101489565A (zh) 2006-05-05 2009-07-22 Isis药物公司 调节pcsk9表达的化合物和方法
AU2007258117B2 (en) 2006-05-05 2013-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
BRPI0719953B8 (pt) 2006-10-02 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade para receptor de il-4 humano
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
US20100040611A1 (en) 2006-11-07 2010-02-18 Sparrow Carl P Antagonists of pcsk9
CA2669424A1 (en) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonists of pcsk9
EP2083860A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme PCSK9 ANTAGONISTS
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP2010510807A (ja) 2006-11-27 2010-04-08 アイシス ファーマシューティカルズ， インコーポレーテッド 高コレステロール血症を治療するための方法
HUE033960T2 (en) 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
WO2008125623A2 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP5425056B2 (ja) 2007-05-15 2014-02-26 エフ．ホフマン−ラ ロシュ アーゲー Ｇタンパク質共役受容体（ｇｐｃｒ）に対する抗体
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20100286021A1 (en) 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
BRPI0818765A8 (pt) 2007-10-26 2016-02-10 Schering Corp Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
ES2658596T3 (es) 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
MX2011009306A (es) 2009-03-06 2011-10-13 Genentech Inc Formulacion con anticuerpo.
CN102695499A (zh) 2009-06-18 2012-09-26 惠氏有限责任公司 小模块免疫药物的冻干制剂
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
EP2483682A1 (en) 2009-10-02 2012-08-08 INSERM - Institut National de la Santé et de la Recherche Médicale Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
WO2011053759A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
RU2548772C2 (ru) 2009-11-20 2015-04-20 Биокон Лимитед Составы антитела
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2545079A2 (en) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CN103328514B (zh) 2010-11-09 2015-12-02 阿尔蒂单抗治疗公司 用于抗原结合的蛋白复合物及其使用方法
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
CA2825838C (en) 2011-01-28 2020-10-27 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
EA201391157A1 (ru) 2011-02-11 2014-02-28 АйАрЭм ЭлЭлСи Антагонисты pcsk9
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
CA2840482C (en) 2011-07-14 2018-10-16 Pfizer Inc. Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
JP2015517579A (ja) 2012-05-25 2015-06-22 カタバシス ファーマシューティカルズ，インコーポレイテッド プロタンパク質転換酵素スブチリシン／ケキシン９型（ｐｃｓｋ９）を低下させる方法
CN104540852B (zh) 2012-08-13 2018-10-02 瑞泽恩制药公司 具有pH-依赖性结合特性的抗-PCSK9抗体
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
PL3055333T4 (pl) 2013-10-11 2020-07-27 Sanofi Biotechnology Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
CN106029096A (zh) 2014-02-14 2016-10-12 瑞泽恩制药公司 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
WO2015140079A1 (en) 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
KR20160132459A (ko) 2014-03-17 2016-11-18 사노피 바이오테크놀로지 심혈관 위험을 감소시키는 방법
CA2955304C (en) 2014-07-16 2023-12-12 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
EP3169353B1 (en) 2014-07-16 2019-12-18 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer

Also Published As

Publication number Publication date
EA201490641A1 (ru) 2014-06-30
ES2953713T3 (es) 2023-11-15
MY170089A (en) 2019-07-04
EP3536712B1 (en) 2023-05-31
CL2014000605A1 (es) 2014-08-22
AU2012308797A1 (en) 2014-03-13
CN103930444B (zh) 2020-08-04
IL231011A0 (en) 2014-03-31
MX2014002158A (es) 2014-05-07
EA028278B1 (ru) 2017-10-31
AU2012308797B2 (en) 2017-06-01
EP2756004A1 (en) 2014-07-23
JP2017206520A (ja) 2017-11-24
JP6158813B2 (ja) 2017-07-05
BR112014005522A2 (pt) 2017-03-21
EP4252857A3 (en) 2023-12-06
KR101964031B1 (ko) 2019-04-02
JP2014527967A (ja) 2014-10-23
IL231011B (en) 2020-01-30
SG2014010524A (en) 2014-06-27
TW201329099A (zh) 2013-07-16
US10076571B2 (en) 2018-09-18
US11116839B2 (en) 2021-09-14
EP2756004B1 (en) 2019-12-25
WO2013039969A1 (en) 2013-03-21
AR087881A1 (es) 2014-04-23
CA2848201C (en) 2020-10-27
US20180333490A1 (en) 2018-11-22
MA35430B1 (fr) 2014-09-01
MX363642B (es) 2019-03-28
US20130243784A1 (en) 2013-09-19
ZA201401114B (en) 2015-04-29
NZ621135A (en) 2016-10-28
EP3536712A1 (en) 2019-09-11
CA2848201A1 (en) 2013-03-21
CN111789944A (zh) 2020-10-20
EP4252857A2 (en) 2023-10-04
CN103930444A (zh) 2014-07-16
KR20140075728A (ko) 2014-06-19
TWI601740B (zh) 2017-10-11
ES2773111T3 (es) 2020-07-09

Similar Documents

Publication Publication Date Title
CO6910163A2 (es) Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de proteína convertasa subtilisina kexina-9 (pcsk9)
DK2710018T3 (da) Makrocykliske forbindelser som proteinkinasehæmmere
SMT201600238B (it) Inibitori di protein chinasi
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
DK3513793T3 (da) Heterocyclylaminer som pi3k-inhibitorer
BR112014012159A2 (pt) tetra-hidrocanabivarina fitocanabinóide
DK2685986T3 (da) Glucosylceramidsyntasehæmmer
EP2675440A4 (en) CYSTEINE INHIBITORS PROTEASES, CATHEPSINES
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
UY34970A (es) Una Plataforma Elevable para Espectáculos Acuáticos
UY33947A (es) Terapias combinadas para malignidades hematológicas
ITTO20120967A1 (it) Maschera per nuoto
BR112013031795A2 (pt) método para tratar uma doença
CO6842021A2 (es) Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos
DE112012002888A5 (de) Pumpenantrieb
DK2550985T3 (da) Plungerstempelkit til medicinsprøjte
ES2641042T8 (es) Procedimiento para la fabricación de un fármaco proteínico
BR112014012099A2 (pt) dispositivo de intertravamento para um conjunto comutador
CO6801691A2 (es) Método para fabricar un endulcorante natural mejorado
DK3044214T3 (da) Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer
BR112013029915A2 (pt) método para a produção de hidrocarbonetos aromáticos monocíclicos
CO6890113A2 (es) Métodos para aislar ácidos 4-cloro-2-fluoro-3-fenilborónicos sustituidos
ES1077835Y (es) Conjunto de frasco para esmalte de uñas magnético